NOZINAN 25 MG
Levomepromazine maleate acid
What it does
Levomepromazine is a medication used to help manage certain mental health conditions.
Commonly used for: schizophrenia, severe anxiety, nausea and vomiting
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:07 · updated 2026-09-21 02:30:19
Drug Interactions
1Pharmacodynamic Warnings
Levomepromazine appears in TABLE 8: Drugs that cause hypotension
Levomepromazine appears in TABLE 9: Drugs that prolong the QT interval
Levomepromazine appears in TABLE 10: Drugs with antimuscarinic effects
Levomepromazine appears in TABLE 11: Drugs with CNS depressant effects
Unknown (1)
Antipsychotics - additive effect
Antipsychotics,secondgeneration(clozapine)cancause constipation,ascanantipsychotics,secondgeneration (olanzapine,quetiapine);concurrentusemightincreasethe riskofdevelopingintestinalobstruction.rAnecdo
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class
About this medicine
Levomepromazine is a medication used to help manage certain mental health conditions.
What it treats
- schizophrenia
- severe anxiety
- nausea and vomiting
How it works
It works by affecting chemicals in the brain to help improve mood and reduce anxiety.
Who it's for
This medication is for adults who have been diagnosed with specific mental health issues.
Drug class
Antipsychotics
Cautions
- • Be cautious if using other medications that lower blood pressure.
- • Avoid medications that may affect heart rhythm.
- • Be careful with drugs that have drying effects on the body.
- • Use caution with medications that can cause drowsiness.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Levomepromazine
BNF-referencedLevomepromazine, also known as Methotrimeprazine, is a phenothiazine antipsychotic primarily used in palliative care settings. It exhibits potent antiemetic properties and is effective for treating severe pain, nausea, and confusion in patients who are unresponsive to other treatments. The drug acts on multiple neurotransmitter systems, which contributes to its wide range of clinical applications.
Indications
- Nausea and vomiting in palliative care
- Pain management in palliative care
- Restlessness and confusion in palliative patients
- Meniere's disease
Dosage
Children: For children aged 1 month to 11 years, the recommended dose is 100–400 micrograms/kg administered over 24 hours. For children aged 12 to 17 years, the dosing range is 5–25 mg, also to be administered over 24 hours.
Adults: For adults, levomepromazine can be administered subcutaneously at an initial dose of 12.5–50 mg over 24 hours, titrated based on response. For acute cases, a dose of 6.25 mg may be given every 2 hours as required, or 12.5–25 mg twice daily.
Mechanism of action
Levomepromazine's antipsychotic effects are primarily due to its antagonism of dopamine receptors in the brain. Additionally, it binds to 5HT2 serotonin receptors, which may further contribute to its therapeutic actions. This dual mechanism allows for effective management of both psychotic symptoms and nausea.
Pharmacodynamics
Levomepromazine possesses pharmacological activity similar to chlorpromazine and promethazine. It exhibits histamine antagonist properties that contribute to its sedative and antiemetic effects. Its central nervous system effects stem from dopamine receptor antagonism, leading to reduced agitation and pain perception in palliative care.
Pharmacokinetics
Levomepromazine is absorbed after oral administration and has a variable bioavailability due to first-pass metabolism. It is extensively metabolized in the liver, primarily through cytochrome P450 enzymes, and its metabolites are excreted in urine. The elimination half-life varies but is generally around 8 to 12 hours. The drug reaches peak plasma concentrations within several hours after administration.
Contra-indications
- CNS depression
- comatose states
- phaeochromocytoma
Adverse effects
- gastrointestinal discomfort
- headache
- nausea
- asthenia
- heat stroke
- cardiac arrest
- hepatic disorders
- allergic dermatitis
- vomiting
Interactions
- phenothiazines
- risk of postural hypotension
Precautions
- Patients receiving large initial doses should remain supine
- history of asthma
- history of peptic ulcer
Pregnancy
Avoid unless clearly necessary-no information available.
Breast-feeding
Use only if potential benefit outweighs risk.
Storage
Store in a cool, dry place away from light.
Formulations
- Levomepromazine 6 mg tablets
- Levomepromazine 25 mg tablets
- Levomepromazine 50 mg tablets
- Levomepromazine 100 mg tablets
- Levomepromazine 25 mg/1 ml solution for injection ampoules
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Levomepromazine
PubChem CID 72287Molecular formula: C19H24N2OS
Mechanism of action
Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role.
Pharmacodynamics
Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.